This study concludes that blood-based Aβ and p-Tau biomarkers represent a significant advance in AD diagnostics, offering non-invasive, cost-effective, and scalable solutions for early detection and therapeutic monitoring. The gene discussed is MAPT; the disease is Alzheimer disease.